Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | ERG | P11308 | 1/20 | 0.75 |
| ▸ | TACR2 | P21452 | 2/20 | 0.68 |
| ▸ | TACR1 | P25103 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26189926 | 0.90 | TACR3 (0.72) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL25224258 | 0.88 | TACR3 (0.69) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL25607405 | 0.88 | TACR3 (0.69) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL30627854 | 0.88 | TACR3 (0.72) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL30627850 | 0.88 | TACR3 (0.72) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL16048688 | 0.88 | TACR3 (1.00) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL14850765 | 0.88 | TACR3 (1.00) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL26189922 | 0.88 | TACR3 (0.69) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL2551146 | 0.87 | TACR3 (0.86) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL2551144 | 0.87 | TACR3 (0.86) | TACR3CYP2C9CYP2C19CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731974-B2 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | OGEDA SA (BE) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731974-B2 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | PKD1, KISS1R, PKD2 | TACR3 98/4885CYP2C9 1511/4885CYP2C19 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.